Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.65 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.60 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | GAPDH | P04406 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952790 | 1.00 | ADK (0.65) | ADKHSPA5HSPA8RXFP1GAPDH | |
| SCHEMBL8494362 | 0.89 | HSPA5 (0.61) | ADKHSPA5HSPA8RXFP1GAPDH | |
| SCHEMBL8494383 | 0.89 | HSPA5 (0.61) | ADKHSPA5HSPA8RXFP1GAPDH | |
| SCHEMBL1144992 | 0.86 | ADK (0.66) | ADKHSPA5HSPA8RXFP1GAPDH | |
| SCHEMBL1144665 | 0.86 | NADK (0.60) | ADKHSPA5HSPA8RXFP1GAPDH | |
| SCHEMBL23498581 | 0.86 | HSPA8 (0.59) | ADKHSPA5HSPA8RXFP1GAPDH | |
| SCHEMBL1144664 | 0.86 | NADK (0.60) | ADKHSPA5HSPA8RXFP1GAPDH | |
| SCHEMBL6434241 | 0.86 | HSPA8 (0.80) | HSPA5HSPA8RXFP1GAPDHHSD17B10 | |
| SCHEMBL1144993 | 0.86 | ADK (0.66) | ADKHSPA5HSPA8RXFP1GAPDH | |
| SCHEMBL6434249 | 0.86 | HSPA8 (0.80) | HSPA5HSPA8RXFP1GAPDHHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584126-B2 | microRNA inhibitors for use in treating metabolic diseases | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2026-03-24 | — | — | US | disclosed |
| EP-3775277-B1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MULTIPLEXDX S R O (SK) | 2025-12-03 | — | — | EP | disclosed |
| EP-3850099-B1 | MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-12404605-B2 | Method for diagnosing diseases using multiplex fluorescence and sequencing | MultiplexDX, s.r.o. (SK) | 2025-09-02 | — | — | US | disclosed |
| CN-112654705-B | MicroRNA inhibitors for use in the treatment of metabolic disorders | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 2024-07-02 | — | — | CN | disclosed |
| US-20230037279-A9 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MultiplexDX, s.r.o. (SK) | 2023-02-02 | — | — | US | disclosed |
| US-20220002812-A1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MULTIPLEXDX S R O (SK) | 2022-01-06 | — | — | US | disclosed |
| CN-113366118-A | Methods for diagnosing disease using multiplex fluorescence and sequencing | 马尔提普莱克斯公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210254067-A1 | MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-08-19 | — | — | US | disclosed |
| EP-3850099-A1 | MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES | Helmholtz Zentrum München Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2021-07-21 | — | — | EP | disclosed |
| CN-112654705-A | micro-RNA inhibitors for use in the treatment of metabolic diseases | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 2021-04-13 | — | — | CN | disclosed |
| EP-3775277-A1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MultiplexDX, s.r.o. (SK) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020070325-A1 | METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING | MULTIPLEX DX (SK) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020053186-A1 | MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-03-19 | — | — | WO | disclosed |
| WO-2017097973-A1 | MODIFIED NUCLEOSIDES | UNIVERSITAET KONSTANZ (DE) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584126-B2 | microRNA inhibitors for use in treating metabolic diseases | TRDMT1, NSUN3, RNGTT | ADK 2941/4885HSPA5 1589/4885HSPA8 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.